Onkologie, Hämatologie - Daten und Informationen

2 Begleitmaßnahmen bei definierter medikamentöser Therapie: Literatur

Autor/en: H.-P. Lipp, C. Bokemeyer, S. Koeppen
Letzte Änderung: 17.12.2014
  • Abid SH, Malhotra V, Perry MC.
    Radiation-induced and chemotherapy-induced pulmonary injury.
    Current Opinion in Oncology 2001;13:242-248. PMID:11429481

  • Anand AJ, Bashey B.
    Newer insights into cisplatin nephrotoxicity.
    Ann Pharmacother 1993;27:1519-1525. PMID:8305788

  • Argyriou A, Alberti P, Briani C et al.
    Incidence, characteristics, and associations of Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: results of a prospective, multicenter international study.
    J Clin Oncol 2012;30 (A9090).

  • Bearman SI.
    Veno-occlusive disease of the liver.
    Current Opinion in Oncology 2000;12:103-109. PMID:10750719

  • Beijers AJ, Jongen JM, Vreugdenhil G.
    Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies.
    The Netherlands Journal of Medicine 2012;70:18-24. PMID:22271810

  • Benoehr P, Krueth P, Bokemeyer C et al.
    Nephroprotection by theophylline in patients with Cisplatin chemotherapy: A randomized, single-blinded, placebo-controlled trial.
    J Am Soc Nephrol 2005;16:452-458. PMID:15590762

  • Blanco JG, Sun CL, Landier W et al.
    Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes - A report From the Children’s Oncology Group.
    J Clin Oncol 2012;30:1415-1421. PMID:22124095

  • Brana I, Tabernero J.
    Ann of Oncol 2010;21:173-179. PMID:20943611

  • Burns LJ.
    Ocular toxicities of chemotherapy.
    Semin Oncol 1992;19:492-500. PMID:1411647

  • Busea JM, Garcia-Teijido P, Losa R et al.
    Treatment of ifosfamide encephalopathy with intravenous thiamin.
    Clin Cancer Res 2003;9:4636-4637. PMID:14555540

  • Capelli B, Chiesa R, Evangelio E et al.
    Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan.
    Br J Haematol 2009;147:554-560. PMID:19747363

  • Cardinale D, Colombo A, Sandri MT et al.
    Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-concverting enzyme inhibition.
    Circulation 2006;114:2474-2481. PMID:17101852

  • Cerosimo RJ.
    Monoclonal antibodies in the treatment of cancer, part 1.
    Am J Health Syst Pharm 2003;60:1531-1548. PMID:12951753

  • Christensen AM, Pauley JL, Molinelli AR et al.
    Resumption of High-Dose Methotrexate After Acute Kidney Injury and Glucarpidase Use in Pediatric Oncology Patients.
    Cancer 2012;118:4321-4330. PMID:22252903

  • Cianci G, Morelli MF, Cannita K.
    Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.
    Br J Cancer 2003;88:1507-1509. PMID:12771913

  • Coleman R, Santoso JT, Lucci J.
    Saline, mannitol, and furosemide in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 2003;52:13-18. PMID:12719883

  • De Jongh FE, van Veen RN, Veltman SJ.
    Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients.
    Br J Cancer 2003;88:1199-1206. PMID:12698184

  • Delforge M, Bladé J, Dimopoulos MA et al.
    Treatment-related peripheral neurophathy in multiple myeloma: the challenge continues.
    Lancet Oncol 2010;11:1086-1095. PMID:20932799

  • Drachtman RA, Cole PD, Golden CB.
    Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol 2002;19:319-327. PMID:12078863

  • Durant J-P, Goldwasser F.
    Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine.
    Anti-Caner Drugs 2002;13:777-780. PMID:12187335

  • Foladore S, Ceccherini R, Leita M.
    Gabapentin in chemo-induced peripheral neuropathy prevention: A phase II open study. Proc Am Soc Clin Oncol 2003;22: Abstract #3089.

  • Gamelin E, Gamelin L, Bossi L, Quasthoff S.
    Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures.
    Semin Oncol 2002;29:21-33. PMID:12422305

  • Gamelin L, Boisdron-Celle M, Delva R et al.
    Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
    Clin Cancer Res. 2004;10:4055-4061. PMID:15217938

  • Grothey A, Nikcevich DA, Sloan JA et al.
    Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.
    J Clin Oncol 2011;29:421-427. PMID:21189381

  • Grunwald MR, Howie L, Diaz LA.
    Takotsubo Cardiomyopathy and Fluorouracil: Case Report and Review of the Literature.
    J Clin Oncol 2012;30:11-14. PMID: 22147738

  • Han CH, Khwaounjoo P, Kilfoyle DH et al.
    Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients.
    BMC Cancer 2013;25:495. PMID:24156389

  • Hartmann JT, Lipp H-P.
    Toxicity of platinum compounds.
    Expert Opin Pharmacother 2003;4:889-901. PMID:12783586

  • Herishanu Y, Lishner M, Kitay-Cohen Y.
    The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine.
    Anti-Cancer Drugs 2002;13:177-179. PMID:11901312

  • Hershman DL, Lacchetti C, Dworkin RH et al.
    Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.
    J Clin Oncol 2014. PMID:24733808

  • Hershman DL, Unger JM, Crew KD et al.
    SWOG S0715: Randomized placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy during adjuvant breast cancer therapy.
    J Clin Oncol 2013;31:2627-2633. PMID: 23733756

  • Huelsenbeck SC, Schorr A, Roos WP et al.
    Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.
    J Biol Chem 2012;287:38590-38599. PMID:23012366

  • Iacovelli R, Palazzo A, Mezi S et al.
    Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.
    Acta Oncol 2012;51:873-879. PMID:22909392

  • Imtiaz S, Muzaffar N.
    Ifosfamide neurotoxicity in a young female with a remarkable response to thiamine.
    J Pak Med Assoc 2010;60:867-869. PMID:21381624

  • Knijn N, Tol J, Koopman M, Werter MJ et al.
    The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
    Eur J Cancer 2011;47:369-374. PMID:21067912

  • Koukourakis MI.
    Amifostine in clinical oncology: current use and future applications.
    Anti-Cancer Drugs 2002;13:181-209. PMID:11984063

  • Krackhardt A, Schwartz S, Korfel A, Thiel E.
    Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure.
    Leukemia Lymphoma 1999;35:631-635. PMID:10609804

  • Kreisman H, Wolkove N.
    Pulmonary toxicity of antineoplastic therapy.
    Semin Oncol 1992;19:508-520. PMID:1411649

  • Kwong YL, Yeung DY, Chan JC.
    Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities.
    Ann Hematol 2009;88:193-201. PMID:19050889

  • Leschke M, Weißendorf S, Wädlich A.
    Kardiale Nebenwirkungen von Radio- und Chemotherapie.
    Besonderheiten bei älteren Menschen.
    Klinikarzt 2011;40:340-347.

  • Levi F, Zidane R, Misser JL.
    Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer.
    Lancet 1997;350:681-686. PMID:9291901

  • Lipp H-P, Bokemeyer C.
    Clinical pharmacokinetics of cytostatic drugs: Efficacy and toxicity.
    In: Lipp H-P (ed). Anticancer drug toxicity: Prevention, management and clinical pharmacokinetics.
    New York, Basel: Marcel Dekker 1999;11-201.

  • Lipshultz SE, Rifai N, Sallan SE et al.
    Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.
    Circulation 1997:96:2641-2648. PMID:9355905

  • Loprinzi CL, Qin R, Dakhil SR et al.
    Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
    J Clin Oncol 2014;32:997-1005. PMID:24297951

  • Lorusso D, Ferrandina G, Greggi S et al.
    Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
    Ann Oncol 2003;7:1086-1093. PMID:12853351

  • Menna P, Salvatorelli E, Minotti G.
    Cardiotoxicity of Antitumor Drugs.
    Chem Res Toxicol 2008;21:978-989. PMID:18376852

  • Mielke S, Mross K, Gerds TA.
    Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anti-Cancer Drugs 2003;14:785-792. PMID:14597872

  • Mordente A, Meucci E, Silvestrini A et al.
    New developments in anthracycline-induced cardiotoxicity.
    Curr Med Chem 2009;16:1656-1672. PMID:19442138

  • Moreau P et al.
    Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized phase 3, non-inferiority study.
    Lancet Oncol 2011;12:431-440. PMID:21507715

  • Morgan KP, Buie LW, Savage SW.
    The Role of Mannitol as a Nephroprotectant in Patients Receiving Cisplatin Therapy
    Ann Pharmacother 2012;46:276-281. PMID:22298599

  • Mousavi SS, Zadeh MH, Shahbazian H et al.
    The protective effect of theophyline in cisplatin nephrotoxicity.
    Saudi J Kidney Dis Transpl. 2014;25:333-337. PMID:24626000

  • Muraki K, Koyama R, Honma Y et al.
    Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer.
    J Thorac Dis 2012;4:562-568. PMID:23205279

  • Nicolao P, Giometto B.
    Neurological toxicity of ifosfamide.
    Oncology 2003;65:11-16. PMID:14586141

  • Nishimura H, Enokida H, Nagano S et al.
    Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury.
    J Artif Organs 2014;17:110-103. PMID:24091438

  • Nissim I, Weinberg JM.
    Glycine attenuates Fanconi syndrome induced by maleate or ifosfamide in rats.
    Kidney Int 1996;49:684-695. PMID:8648909

  • O'Sullivan JM, Huddart RA, Norman AR.
    Prediciting the risk of bleomycin lung toxicity in patients with germ-cell tumours.
    Ann Oncol 2003;14:91-96. PMID:12488299

  • Osswald H, Schnermann J.
    Methylxanthines and the kidney.
    Handb Exp Pharmacol 2011;200:391-412. PMID:20859805

  • Peerzada MM, Spiro TP, Daw H.
    Pulmonary toxicities of biologics: a review.
    Anti-Cancer Drugs 2010;21:131-139. PMID:20016372

  • Pelgrims J, De Vos F, Van den Brande J.
    Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
    Br J Cancer 2000;82:291-294. PMID:10646879

  • Peltier AC, Russell JW.
    Recent advances in drug induced neuropathies.
    Curr Opin Neurol 2002;15:633-638. PMID:12352008

  • Perez EA, Rodeheffer R.
    Clinical cardiac tolerability of trastuzumab.
    J Clin Oncol 2004;22:322-329. PMID:14722042

  • Perry MC.
    Hepatotoxicity of chemotherapeutic agents.
    Semin Oncol 1982;9:65-74. PMID:7071610

  • Piccolo J, Kolesar JM.
    Prevention and treatment of chemotherapy-induced peripheral neuropathy.
    Am J Health Syst Pharm 2014;71:19-25. PMID:24352178

  • Quasthoff S, Hartung HP.
    Chemotherapy-induced peripheral neuropathy.
    J Neurol 2002;249:9-17. PMID:11954874

  • Roth P, Stupp R, Eisele G, et al.
    Treatment of primary CNS lymphoma.
    Curr Treat Options Neurol 2014;16:277. PMID:24343307

  • Rowinski EK, Chaudhry V, Cornblath DR.
    Neurotoxicity of taxol.
    J Natl Cancer Inst 1993;15:107-115. PMID:7912516

  • Sayer HG, Will U, Schilling K.
    Hepatic veno-occlusive disease (VOD) with complete occlusion of liver venules after tandem autologous stem cell transplantation - successful treatment with high-dose methylprednisolone and defibrotide.
    J Cancer Res Clin Oncol 2002;128:148-152. PMID:11935301

  • Sereno M, Gutierrez G, Rodriguez-Antona C et al.
    Genetic polymorphisms of SCNA9 as predictive markers of oxaliplatin-induced neuropathy.
    J Clin Oncol 2012;30 (A9073)

  • Serrano C, Cortes J, De Mattos-Arruda L et al.
    Trastuzumab-related cardiotoxicity in the elderly: a role for cardiaovsascular risk factors.
    Ann Oncol 2012;23:897-902. PMID:21828361

  • Shah MS, Jeevangi NK, Joshi A et al.
    Late-onset hepatic veno-occlusive disease post autologous peripheral stem cell transplantation successfully treated with oral defibrotide.
    J Cancer Res Ther 2009;5:312-314. PMID:20160371

  • Shamash J, Earl H, Souhami R.
    Acetazolamide for alkalinisation of urine in patients receiving high-dose methotrexate.
    Cancer Chemother Pharmaco. 1991;28:150-151. PMID:2060085

  • Sioka C, Kyritisis A.
    Central and peripheral nervous system toxicity of common chemotherapeutic agents.
    Cancer Chemother Pharmacol 2009;63:761-767. PMID:19034447

  • Skinner R.
    Nephrotoxicity and urotoxicity of chemotherapeutic agents.
    In: Lipp H-P (ed). Anticancer drug toxicity: Prevention, management and clinical pharmacokinetics.
    Basel, New York: Marcel Dekker 1999;321-346.

  • Skinner R.
    Strategies to prevent nephrotoxicity of anticancer drugs.
    Curr Opin Oncol 1995;7:310-315. PMID:7578377

  • Sioka C, Kyritsis AP.
    Central and peripheral nervous system toxicity of common chemotherapeutic agents.
    Cancer Chemother Pharmacol 2009;63:761-7. PMID:19034447

  • Smith EM, Pang H, Cirrincione C et al.
    Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.
    JAMA 2013;309:1359-67. PMID:23549581

  • Stanford BL, Zondor SD.
    Bortezomib treatment for multiple myeloma.
    Ann Pharmacother 2003;37:1825-1830. PMID:14632585

  • Sun Y, Liu B, Liu P et al
    A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine (ALC) in treatment of chemotherapy-induced peripheral neuropathy (CPIN).
    J Clin Oncol 2012;30: supp;abstr 9017

  • Swain SM, Vici P.
    The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.
    J Cancer Res Clin Oncol 2004;130:1-7. PMID:14564513

  • Takimoto CH, Lu Z-H, Zhang R, Liang MD.
    Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.
    Clin Cancer Res 1996;2:477-481. PMID:9816193

  • Tuxen MK, Hansen SW.
    Neurotoxicity secondary to antineoplastic agents.
    Cancer Treat Rev 1994;20:191-214. PMID:8156541

  • Verschraagen M, Boven E, Ruijter R.
    Pharmacokinetics and preliminary clinical data of the novel chemoprotector BNP7787 and cisplatin and their metabolites.
    Clin Pharmacol Ther 2003;74:157-169. PMID:12891226

  • Wang MS, Davis AA, Culver DG, Glass JD.
    WldS mice are resistant to paclitaxel (taxol) neuropathy.
    Ann Neurol 2002;52:442-447. PMID:12325073

  • Werling LL, Lauterbach EC, Calef U.
    Dextromethorphan as a potential neuroprotective agent with unique mechanism of action.
    Neurologist 2007;13:272-293. PMID:17848867

  • Willemsen AECA, van Herpen CML.
    mTOR inhibitor-related pulmonary toxicity; incidence even higher.
    Acta Oncol. 2013;52:1234. PMID:23409770

Arbeitsgemeinschaft Supportive Maßnahmen in der Onkologie, Rehabilitation u. Sozialmedizin d. Deutschen Krebsgesellschaft e.V. [Mehr]
Nach wie vor online verfügbar: die noch nicht aktualisierten Kapitel des Buches "Supportiv- therapie bei malignen Erkrank- ungen", bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag", 2006. [Mehr]
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch: